Overview

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Status:
RECRUITING

Trial end date:
2029-12-31

Target enrollment:

Participant gender:

Summary

This is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with histologically and pathologically confirmed resectable esophageal squamous carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Peking University Cancer Hospital & Institute

Treatments:

130-nm albumin-bound paclitaxel
camrelizumab
Cisplatin